COGNICURRENT

Feb 3 • 17:17 UTC • 🇩🇰 Denmark • Politiken

Dismal prediction: If Novo is right, 2026 could become the company's worst year in this millennium

Novo Nordisk is facing a potential downturn as sales growth from weight loss drugs slowed, despite surpassing expectations with Wegovy sales reaching 21.9 billion kroner in the fourth quarter of 2025.

#novo nordisk #wegovy #sales #finance #mike doustdar

Read Original Back to Feed

📡 Similar Coverage

🇩🇰 Denmark Feb 3 • 17:17 UTC

Dismal prediction: If Novo is correct, 2026 could be the worst year of this millennium

Politiken

🇬🇷 Greece Feb 4 • 08:35 UTC

Novo Nordisk: 18% 'plunge' in stocks after the 'cold shower' for 2026 forecasts

Naftemporiki

🇩🇰 Denmark Feb 3 • 17:17 UTC

Novo lander growth at six percent with annual report

Politiken

🇩🇰 Denmark Feb 4 • 08:49 UTC

Novo-chef: We are affected by two factors pulling in the wrong direction

Politiken

🇩🇪 Germany Feb 4 • 13:17 UTC

"The market is relatively saturated - we see no big growth prospects anymore"

Die Welt

🇪🇸 Spain Feb 4 • 10:02 UTC

Novo Nordisk's shares plummet amid strong sales forecast drop for Ozempic and Wegovy this year

El País